Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Mouthwash for Oral and Pharyngeal Toxicity
NCT05331131Phase 2Withdrawn
- Sponsor
- Northwell Health
- Start
- Sep 2022
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine transdermal patch in oral mucositis (OM) and mucositis, sponsored by Northwell Health. Primary endpoint: Assessing Pain Response at 14 days. Planned start Sep 2022; status: withdrawn.
02
Drugs
ketamine transdermal patch
03
Conditions
oral mucositis (OM)mucositis
Beyond the preview
Go deeper on NCT05331131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05331131.